Author | Susan G. Arbuck, MD

Articles

Clinical Status and Optimal Use of Topotecan

November 01, 1997

Topotecan (Hycamtin) is a promising new topoisomerase I-targeting anticancer agent that first entered clinical trials in 1989 under National Cancer Institute sponsorship in collaboration with SmithKline Beecham. In 1996, it